Peptide receptor radionuclide therapy, abbreviated PRRT, is a type of radionuclide therapy that uses a radiopharmaceutical targeting peptide receptors to deliver localized treatment, typically for neuroendocrine tumors.
Facts
Connections
Associated With
Treats
Source Peptide receptor radionuclide therapy (Wikipedia)
Source Peptide receptor radionuclide therapy (Wikipedia)
Sources
1. Wikipedia
Wikipedia contributors, Wikimedia Foundation
Wikidata: Peptide Receptor Radionuclide Therapy
Wikidata Q55629467, class allow-list match (w-wdresolver-0926)View the Source Peptide receptor radionuclide therapy (Wikipedia)
https://en.wikipedia.org/wiki/Peptide_receptor_radionuclide_therapy, lead section
Peptide receptor radionuclide therapy (PRRT) is a type of radionuclide therapy, using a radiopharmaceutical that targets peptide receptors to deliver localised treatment, typically for neuroendocrine tumours (NETs).
Treats: Neuroblastoma, Applications
In most cases PRRT is used for cancers of the gastroenteropancreatic and bronchial tracts, and in some cases phaeochromocytoma, paraganglioma, neuroblastoma or medullary thyroid carcinoma.
Treats: Paraganglioma, Applications
In most cases PRRT is used for cancers of the gastroenteropancreatic and bronchial tracts, and in some cases phaeochromocytoma, paraganglioma, neuroblastoma or medullary thyroid carcinoma.
View the SourceReader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.